UROLOGIX INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-11-08: Form 8-K/A; Period of report 2013-06-28; Description 9.01 Financial Statements and Exhibits; Details 9.01.
- 2013-11-08: Form 8-K; Period of report 2013-11-07; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2013-10-30: Form 8-K; Period of report 2013-10-29; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2013-08-21: Form 8-K; Period of report 2013-08-20; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-11-08 | 8-K/A | 2013-06-28 | 9.01 Financial Statements and Exhibits | 9.01 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. | urologix134662_8ka.htm |
| 2013-11-08 | 8-K | 2013-11-07 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Urologix, Inc. (the “Company”) held its 2013 Annual Meeting of Shareholders (the “Annual Meeting”) on November 7, 2013 at the Sheraton Minneapolis West, 12201 Ridgedale Drive, Minnetonka, Minnesota, beginning at 4:00 p.m., local time. | urologix134669_8k.htm |
| 2013-10-30 | 8-K | 2013-10-29 | 2.02 Results of Operations and Financial Condition | 2.02 Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on October 29, 2013 disclosing material non-public information regarding the Company’s results of operations for the first fiscal quarter of fiscal year 2014 ended September 30, 2013 and hereby furnishes as Exhibit 99.2 statements of Brian J. Smrdel, the Company’s Chief Financial Officer, made on October 29, 2013 at a telephone conference relating to the quarter ended September 30, 2013 results. | urologix134521_8k.htm |
| 2013-08-21 | 8-K | 2013-08-20 | 2.02 Results of Operations and Financial Condition | 2.02 Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on August 20, 2013 disclosing material non-public information regarding the Company’s results of operations for the fourth fiscal quarter and fiscal year 2013 ended June 30, 2013. | urologix133633_8k.htm |
| 2013-08-20 | 8-K | 2013-08-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 14, 2013, the Compensation Committee of the Board of Directors (the “Committee”) of Urologix, Inc. (the “Company”) recommended, and the Board of Directors approved, payouts under the cash incentive program for fiscal year 2013 that was adopted on August 10, 2012 (the “2013 Incentive Plan”) to Gregory J. Fluet, the Company’s Chief Executive Officer; Brian J. Smrdel, the Company’s Chief Financial Officer; and Lisa A. Ackermann, the Company’s Executive Vice President, Sales and Marketing (collectively, the “Executives”). | urologix133614_8k.htm |
| 2013-07-05 | 8-K | 2013-06-28 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 On June 28, 2013, Urologix, Inc. (the “Company”) entered into a Restructuring Agreement and Amendment to Transaction Documents (the “Restructuring Agreement”) with Medtronic, Inc. (“Medtronic”) and Medtronic VidaMed, Inc. The Restructuring Agreement relates to $7.5 million owed by the Company to Medtronic under the Transaction Documents between the parties each dated September 6, 2011, which include the Transition Services and Supply Agreement (“TSSA”), License Agreement (“License Agreement”), Acquisition Option Agreement and Asset Purchase Agreement. | urologix133102_8k.htm |
| 2013-06-05 | 8-K | 2013-06-05 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On June 5, 2013, the Board of Directors of Urologix, Inc. (the “Company”) determined to take steps to voluntarily remove the Company’s common stock from listing on The NASDAQ Stock Market, LLC (“Nasdaq”) and also authorized the Company’s common stock to be quoted on a marketplace within the OTC Markets Group. | urologix132663_8k.htm |
| 2013-05-23 | 8-K | 2013-05-21 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On May 21, 2013, Urologix, Inc. (the “Company”) received formal notice from The NASDAQ Stock Market LLC (“NASDAQ”) indicating that, as of the quarter ended March 31, 2013, the Company did not satisfy the $2.5 million stockholders’ equity requirement for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Listing Rule 5550(b). | urologix132450_8k.htm |
| 2013-05-02 | 8-K | 2013-05-01 | 2.02 Results of Operations and Financial Condition | 2.02 Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on May 1, 2013 disclosing material non-public information regarding its results of operations for the third quarter of fiscal year 2013 ended March 31, 2013. | urologix132125_8k.htm |
| 2013-04-18 | 8-K | 2013-04-16 | 8.01 Other Events | 8.01 As previously reported, Urologix, Inc. (the “Company”) requested a hearing before a NASDAQ Listing Qualifications Panel (the “Panel”) at which it petitioned for continued listing of its common stock pending its return to compliance with all applicable listing requirements. | urologix131828_8k.htm |
| 2013-04-08 | 8-K | 2013-04-08 | 8.01 Other Events | 8.01 On April 8, 2013, Urologix, Inc. (the “Company”) issued a press release, attached hereto as Exhibit 99.1, reporting that the Company has obtained the necessary regulatory clearances and permits to sell the Prostiva RF Therapy System in the United States under its own quality system and labeling. | urologix131648_8k.htm |
| 2013-03-06 | 8-K | 2013-02-28 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On February 28, 2013, Urologix, Inc. (the “Company”) dismissed its independent public accounting firm, KPMG LLP. | urologix131043_8k.htm |
| 2013-02-06 | 8-K | 2013-02-05 | 2.02 Results of Operations and Financial Condition | 2.02 Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on February 5, 2013 disclosing material non-public information regarding its results of operations for the second quarter of fiscal year 2013 ended December 31, 2012. | urologix130489_8k.htm |
| 2013-01-30 | 8-K | 2013-01-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 25, 2013, the Board of Directors of Urologix, Inc. (the “Company”) appointed Gregory J. Fluet as the Company’s Chief Executive Officer and elected him as a director to serve until the Annual Meeting of Shareholders following the Company’s fiscal year 2015 or until his successor is elected and shall qualify. | urologix130353_8k.htm |
| 2013-01-29 | 8-K | 2013-01-23 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On January 23, 2013, Urologix, Inc. (the “Company”) received a letter from The NASDAQ Stock Market LLC stating that the Company has not regained compliance with the minimum bid price requirement of Rule 5550(a)(2) within the 180 calendar day compliance period that ended on January 22, 2013 and that the Company’s common stock is scheduled to be delisted from The Nasdaq Capital Market as of the open of business on February 1, 2013, unless the Company requests a hearing before a NASDAQ Listing Qualifications Panel (the “Panel”). | urologix130329_8k.htm |